CM 2008 promises to deliver comprehensive coverage on the most current thinking, practices and technology in CM. You will take home how to:

- Drive your company’s drug discovery success by ensuring quality processes from Compound Management, into Medicinal Chemistry decisions and out of Focused Screening
- Utilise the latest analytical characterisation technology to generate valuable QC data to incorporate into lead discovery decision making
- Implement low-volume liquid handling and modern automation techniques to improve efficiency and accuracy of your compound handling
- Successfully transport compounds globally and utilise outsourcing options to improve efficiency and flexibility – Don’t miss Pfizer’s session on their decision to outsource their neat sample bank
- Adapt the CM role to meet the needs of evolving hit discovery tactics to ensure smooth and successful operations

*New for CM 2008*

- Exclusive Focus Day on How to Improve the Critical Interface and Workflow between CM, Screening & Research Teams – learn how you can contribute to this key growth opportunity in your company
- Build relationships at the pre-conference Welcome Drinks, in addition to the structured Networking Reception and announcement of the ‘Compound Manager of 2008’ award winner
- Access and network with delegates of the Lead-Finding Screening 2008 conference during joint roundtable discussions, networking occasions, workshops and the Focus Day on Interfaces
- Pre-conference interactive workshop on Closing the gap - Integration of Compound Management with High Throughput Screening data management systems and LIMS
10.00 Opening Remarks from Chairperson
Outlining expected outcomes of the Focus Day and active role of each person taking part
This Focus Day will be used to understand the varying needs of each department and to establish workable solutions toward more stable workloads, optimised, efficient processes from store to screen, and how we can contribute to lead discovery success.

Terry Wood, Head of Liquid Store Centre of Emphasis, Pfizer Global R&D

10.10 Breakout Brainstorming Sessions
Understanding and defining the limitations and expectations of each department
Screeners, Compound Managers & Project leaders will break into three groups to lay out what their expectations are for their colleagues; how they feel the other team can work more in-line with their requirements; and devise some workable suggestions for improvement. Suggestions will be written out on white-boards for discussion points in this afternoon’s group discussion.

11.00 CM Perspective: Opportunities and realistic cooperative efforts – how we can work together to contribute to lead discovery success
- Current challenges and the successful steps we’ve taken to overcome them
- Examples of how improved quality compounds are becoming more lead-like hits
- Discussing the level of cooperation and changes that need to occur to ensure efficient operations between teams
- Tools and processes we can work together to implement to increase efficiency of molecules going thru lead discovery
- Future directions and goals of how we can contribute to speeding up R&D

Janet Cheetham, Executive Director, Amgen

11.40 Screening Perspective: Absolute necessities and how CM can contribute to successful screening
- Rolling with the changes - With technology and assay approaches advancing, so do the expectations on CM
- Describing where and how we see opportunities in process efficiencies
- Taking a collaborative approach with our CM team
- The new UK CM system – how we expect operations to develop and improve
- Bottom line – what we need from CM and research teams to make our job easier, and more successful

Jenny Stables, Head of Cellular HTS, GlaxoSmithKline

12.20 Lunch

13.20 hERG, a Cardiac Safety Assay Case Study: Leveraging Organon’s new IT infrastructure to standardise assays, track compounds and improve the overall quality process and workflows from store - site - screen
- Establishing one streamlined, integrated workflow with Medicinal Chemistry
- Deciding on and implementing software to standardise assay formats
- Using examples to demonstrate how a bar-coded system helps monitor quality and enables full trackability to know what exactly is being screened

14.00 Building a u-HTS system to be integrated with Genentech’s new CM store for smooth and efficient advanced screening
- Advancing Genentech’s small molecule R&D by developing a u-HTS system for rapid screening
- Offering high quality service and reliable automation to any research team conducting assays
- Future expectations of the impact of the integrated u-HTS and CM store to Genentech’s business

Tim Dawes, Sr. Scientific Manager, Early Leads, Genentech

14.40 Coffee Break

15.00 AstraZeneca’s new thinking: Developing a more direct process and defined workflow
- Recent initiatives to improve our relationship with CM and the importance interface into screening
- How we are establishing more direct processes from storage to screening
- Implementing an efficient screening system that CM can access and use
- Discussing an agreeable turnaround time for assay ready plates - how can we maximise the value of this method?

Dr. Eric Tang, Director, Oncology Automation Screening Support Team, AstraZeneca

15.40 Defining best practice interface opportunities & Examining the impact of our efforts on lead discovery
- Key points and remaining issues from this morning’s breakout sessions
- Key take-away lessons to improve critical interfaces in your lead discovery
- Measuring our integration efforts impact:
  - Have hits and subsequently SARs increased due to quality of compounds going into screening?
  - Have the number of lead optimisation projects increased due to higher quality processes being implemented by CM and Screening?
- Future expectations of the impact of the integrated u-HTS and CM store to Genentech’s business

Panelists:
- Ricardo Macarron, Ph.D., Vice President of Compound Management, GlaxoSmithKline & President of the SBS
- Janet Cheetham, Executive Director, Amgen
- Sylviane Komesli, Section Head Molecular Pharmacology, Organon, a part of Schering-Plough Corporation
- Dr. Eric Tang, Director, Oncology Automation Screening Support Team, AstraZeneca
- Jenny Stables, Head of HTS, GlaxoSmithKline
- Terry Wood, Head of Liquid Store Centre of Emphasis, Pfizer Global R&D

16.20 Conclusions and closing remarks

Pre-Conference Workshop: 20th May 2008

16.30 - 19.30
Closing the gap - Integration of Compound Management with High Throughput Screening data management systems and LIMS
High throughput screening (HTS) is no longer the bottle neck in drug discovery; thousands of data points can be screened in many target assays resulting in mountains of data to analyse. Compound Management groups have answered this increased capacity by automating sample storage, retrieving and plating, and how we can provide tools to provide thousands of data points to HTS groups.

However key challenges remain; the right screening result must be associated with the right compound ID. Compound management systems do not always integrate with assay management systems or LIMS systems resulting in reduced cycle time; slowing down the process of hit follow up and lead identification. This workshop will explore challenges like this, and examine different options for integrating the physical movement of samples and plates from automated systems with virtual data management systems to ensure the correct assay result is associated with the correct compound ID. The interactive discussion forum will examine:
- Case studies on how VWorks integrates with custom or commercial LIMS systems through an open architecture and exposed API
- Informatics interface challenges between Compound Management and HTS groups

Workshop Leader: Velocity 11

CM 2008 Welcome Drinks Reception & Networking Opportunity
From 19.00 - Take the time after today’s Focus Day and workshop to relax before the conference, meet up with familiar faces again and enjoy informal networking with your industry colleagues.
8.15 Registration and Coffee

9.00 Pharma IQ Welcome

9.05 Chairperson Opening Remarks
Christine Rigby, Associate Director, Global Compound Sciences, AstraZeneca

9.15 Drug Discovery today: Compound Management’s role in a stressed environment
- Challenges of Drug Discovery today
- Evolution of hit discovery tactics and their impact on CM
- Role of CM in adapting to changes and contributing to lead discovery success
- Valuable lessons in improving the quality processes from store to screen
- Responding to the current environment by improving the quality of CM operations and corporate compound collections

10.00 The Management of Compound Management: How to get buy in for CM
- Managing change in the collaborative role of CM in the drug discovery organisation – how can we be most flexible in our integrated role?
- Responding to new requirements and trends in target based screening
- The secret to success of managing a CM team
- Steps on how to demonstrate the value of CM to key partners

10.30 Morning refreshments

11.00 Global Challenges in Compound Management; Optimising workflows, improving customer service and contributing to the overall performance of Drug Discovery
Over the last decade many companies have made large investments in Compound Management storage, ‘high tech’ automated robotic systems, low volume liquid handling and analytical characterisation technology. Leadership of AstraZeneca’s global CM task force across 9 sites has given insight of the challenges that large Pharma face including:
- The benefits of a highly motivated global CM Network
- Streamlining processes and optimising performance at the global level
- Maximising return on local and global investments - Delivering New capabilities
- Ensuring customer focused delivery and establishing global service level agreements
- Understanding risk and managing costs
- Ensuring global synergies

11.45 Establishing an open access, environmentally controlled Compound Management facility in Australia
- Evaluation factors for choosing a system configuration consisting of three main building blocks (microtube store, sample processing unit and microplate store)
- How we intend to preserve sample integrity for extended (5-6 years) periods of time
- Implementing environmentally controlled plate and tube storage with sample processing to ensure that compound integrity is maintained without compromising flexibility
- Facilitating collaborations between different groups of scientists by leveraging a unique IP model, current HTS infrastructure and the new fully integrated compound handling system
- A view to the future – adopting this modular approach allows future capacity building and throughput increases to be realised with minimal disruption to on-going operations

12.30 Lunch and Networking time in Exhibition

13.45 Discovering small molecules at Tibotec: Automated anti HIV drug screening platform at a medium-size pharmaceutical company
- Storing test compounds in DMSO solutions in an automated storage system with optimised environmental conditions
- Using automated cell-based assay with fluorescent read-out on a laser microscope to investigate anti-HIV activity
- Working with a nanoliter liquid handling device for primary screening and transferring compound libraries into assay plates

14.30 Generating valuable QC data and utilising it in lead discovery decision making
- Providing real-time information on an open access system to medicinal chemists
- Throughput vs. quality: Describing the correlation of low throughput data vs. high throughput data
- Different data for different folks – discussing the varying perceived value of data
- Making a positive overall impact on drug discovery with QC efforts
- A look at progress made with acoustic technology

15.15 Does Modern Medicinal Chemistry incorporate the valuable QC purity and concentration data to decide what to screen – could we have a positive impact on attrition?
- Using valuable data to stay in a competitive market to produce viable drug leads, candidates and products
- Transferring ‘knowledge’ of compounds into decisions on which compounds to screen
- Discussing best approaches to growing and developing optimal QC stock and a results-based library

16.00 Afternoon refreshments

16.30 During each roundtable, the facilitator will present a short case study as a benchmark for a 60 minute discussion and question session. Attendees will get a comprehensive review of the surrounding issues, technical capabilities and differing end-user views. You will also get answers to many questions and new innovative ideas to take back and apply to your compound management work.

A) Analytical Methods in CM – strengths and weaknesses for high throughput NMR as qualitative and quantitative analytic method
Roundtable Leader: Dr. Till Kühn, Product Manager, Bruker BioSpin AG

B) Evaluating technology available for low volume liquid handling and evaluating cost vs. benefit
Roundtable Leader: Dr. Eric Tang, Director, Oncology Automation Screening Support Team, AstraZeneca

C) Collection lifecycle – Discussing best practices re-stocking, updating a successful compound library
Comparing available technologies for automated use of 1538 compound storage plates with and their impact on CM and Screening operations
Roundtable Leader: Claude Dufresne, Senior Investigator, Merck Research Laboratories

D) CM / Screening interface challenges: Key lessons to improving processes store to screen

17.30 Summary of stimulating roundtable discussions

18.00 Close of Day One

18.30 Structured Networking Drinks Reception for both CM and Screening conference delegates
Join your peers in Compound Management, Screening, Lead Discovery / Finding, and Medicinal and Analytical Chemistry to catch up on the latest industry news and take part in, what we like to call, ‘Cross Networking’.

Cross Networking brings together the right people across different functions in an organisation, that can collaborate, network to have a positive, successful impact on their contribution to their company.

Participants will be invited to take part in the ‘Solve the Riddles’ networking game. The grand prize winner will receive a Waterproof Digital Camera.

Announcement of the ‘COMPOUND MANAGER OF 2008’ Award
Part of advancing the science of CM is promoting key contributors in the field. Take this opportunity to recognise your colleague’s significant contributions to CM. Nominate them at www.compoundmanager.com
Implementing 100% DMSO workflows and nanolitre QC follow-up process: Grouping and assessing Optimising plate storage formats to streamline Acoustic case study: AstraZeneca technology

Case Study: Compound identity, purity and Case Study: Streamlining the workflow from bottle to

ensuring maximum quality and downstream success

challenges in Cross-Border Transportation and Compliance  
• Working with and educating the various regulatory agencies and custom officials to interpret and implement new US laws
• Training and awareness of employees to overcome common local challenges, record retention, metrics gathering, compound valuation and potential custom audits
• Utilising new software to standardise processes and to enable internal controls
• Case Study - Key lessons learned that have reduced transit time and custom delays
• Global acquisition of compounds: Challenges, concerns, and cultural assessment of chemical samples between countries
• Knowing how to handle controlled substances during transportation of compounds

Dr. Snehal Bhatt, Manager, Automatic Liquid Store, GlaxoSmithKline

GLOBAL LOGISTICAL CHALLENGES IN THE CHEMICAL COMPOUND SUPPLY CHAINS, CROSS-BORDER TRANSPORTATION AND REGULATORY COMPLIANCIES

Shipping chemical compounds world-wide – Outlining the key

A proactive approach to monitoring and tracking compound quality assurance

• Best practice technology and data use
• Meeting the significant challenges in a high throughput environment with tight timelines
• Reviewing the options available, benefits and drawbacks and techniques employed at AstraZeneca

Isabel Charles, Associate Principle Scientist, Global Compound Sciences, AstraZeneca

QC follow-up process: Grouping and assessing compounds to ensure maximum quality and downstream success

• Deciding the best approaches to categorise and share valuable QC data
• Grouping compounds based on several parameters to ensure information is easily accessed and utilised
• Reducing cost and the number of screens by weeding out poor quality compounds before screening
• Giving examples of how the QC follow up process at Novartis is helping improve downstream lead discovery

Dr. Ingo Muckenschnabel, Laboratory Head, Analytics, Novartis Pharma AG

Case Study: Compound identity, purity and concentration - the challenges of confirming the third dimension of sample quality using CAD detection

• Evaluating the use of CAD detection as a solution for measuring compound concentration
• Using this additional indicator of compound quality to benefit data interpretation for both low and high throughput assays
• Assessing the reliability of the CAD system
• Illustrating precision and accuracy of measurements through examples

Ian Sinclair, QA Specialist, Global Compound Sciences, AstraZeneca

COMDECOM: Predicting COMpound DEComposition in DMSO solution

• The COMDECOM dataset is generated of 15,000 compounds selected by seven pharmaceutical companies
• Monitoring stability in accelerated thermal, hydrolytic and oxidative decomposition testing
• The predictive model: Development of an algorithm to flag compounds that are likely to decompose and therefore saving decomposition testing

Dr. Emrin Zitha-Bovens, Manager Quality Control, Specs

Bayer Schering Pharma - Integration of CM and chemical discovery processes post-acquisition: Building unified single processes for efficient and productive operations

• Post-acquisition challenges: Identifying the key barriers ahead and how we intend to overcome them
• Working toward harmonised processes and clear responsibilities to optimally supply scientists globally
• Narrowing the gap between chemistry, biology and CM mind-sets: How we are working toward one common goal

Dr. Timo Flessner, Director, Head of Medicinal Chemistry 5, Bayer Schering Pharma

Implementing 100% DMSO workflows and nanolitre liquid handling at the Pfizer HTS Centre of Emphasis

• Knowing how to handle controlled substances during transportation of compounds

Joe Bradley, HTS Centre of Emphasis, Pfizer

Acoustic case study: AstraZeneca technology application and results

• Assessment of current acoustic technology available – have we found a HT instrument?
• Practical implementation of acoustic technology – describing the barriers overcome to get up and running
• Acoustic dispensing & acoustic mixing – a dynamic duo excelling our compound and screening operations
• Best practices using the technology
• Future directions

Karen Roberts, Automation Specialist, AstraZeneca

Optimising plate storage formats to streamline focused libraries screening: Automated use of lidded 1536 storage plates

• Assessing automated solutions for 1536 storage plate handling: Limitations and positive aspects
• Describing the evaluation and use of new lid designs, paired with acoustic dispensing compatible plates
• Increasing the rapid availability of various screening modalities to a wider range of targets
• Using examples to demonstrate how this concept is improving the implementation of the integrated ‘store and screen’ paradigm

Claude Dufrène, Senior Investigator, Merck Research Laboratories

Case Study: Streamlining the workflow from bottle to plate with a fully integrated HT system for compound handling and screening

• Choosing the technology and establishing the system for one streamlined workflow
• Total automation from storage to screening
• How our streamlined workflow contributes to successful screening and making our biology colleagues happy
• Extending capacity of CM facilities to meet the increasing demands of our drug discovery efforts

Dr. Wolfgang Roeben, Head of Global Logistics, Bayer CropScience AG

Day Two 22nd May 2008

Dr. Snehal Bhatt, Manager, Automatic Liquid Store, GlaxoSmithKline

“Great as usual - best place to have face-to-face conversations with leaders in the CM community” GlaxoSmithKline
Compound Management & Integrity 2008 will provide the perfect platform for CM automation, informatics, sample processing and analytical technology providers to demonstrate their offerings to potential clients. From our research, we understand that drug discovery organisations throughout Europe and looking for more stable, robust technologies to help measure and improve their compound identity, purity and quantity. Senior-level delegates are also interested in improving automation efficiency and establishing easy-to-use informatics infrastructures. Join us at CM 2008 to explore the technical CM needs of drug discovery companies in Europe and develop new business relationships.

For more information on Sponsorship or Exhibition Opportunities, please call Gal Cohen on +44 (0)20 7368 9491 or email gal.cohen@iqpc.co.uk

JOIN THE CONFERENCE AS A TEAM
Pharma IQ recognises the value of learning in teams. Maximise your conference networking opportunities and ensure an integrated approach is taken to apply new learnings when you return to the office. See back page for team discount details.

Media Partners

“Most valuable conference for CM. Excellent presentations, good networking as a source of new ideas for implementation” F. Hoffman La Roche

“Great speaker panel covering a variety of issues. As always a good meeting where the whole compound management family is present, keep up the good work.”

Specs

“A good mix between several comp. A good conference, very focussed on issues that I deal with on a daily basis. Good to hear that almost everyone is dealing with the same issues.”

Biovitrum AB

“Overall it’s a great composition of speakers. This is one of the most interesting/enjoyable events.”

AstraZeneca
Delegate Information

DELEGATE  □ Mr □ Mrs □ Miss □ Ms □ Or □ Other
First Name ____________________________
Family Name ____________________________
Position ____________________________
Email ____________________________
Organisation ____________________________
Address ____________________________
Phone ____________________________
Fax ____________________________

Cancellations & Substitutions

PAYMENT is due in full upon completion and return of the registration form. Due to limited conference space we advise early registration and payment by credit card to avoid disappointment. Your registration will not be confirmed until payment is received. Admission to the conference will be refused if payment has not been received.

CANCELLATION AND SUBSTITUTION POLICY
Provided the fee has been paid in full, substitutions at no extra charge can be made up to 7 business days before the start of the conference. Cancellations must be received in writing or by fax to +44 (0)20 7368 9301, more than 7 days before the conference is to be held in order to obtain a full credit for any future conference. Cancellations received 7 days or less including the seventh day prior to the conference will not be credited. In the event that IQPC cancels an event payments received after the cancellation date will be credited towards attendance at a future conference, or in the event of postponement by IQPC, a rescheduled date. Credit notes remain valid for twelve months. IQPC reserves the right to postpone or cancel an event, to change the location of an event or to alter the advertised speakers for an event. IQPC is not responsible for any loss or damage as a result of substitution, alteration, postponement, or cancellation of an event due to causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism, or hostility.

SPEAKER CHANGES Occasionally it is necessary for reasons beyond our control to alter the content and timing of the programme or the identity of the speakers.

DATA PROTECTION Personal data is gathered in accordance with the Data Protection Act 1998. Your details may be passed to other companies who wish to communicate with you offers related to your business activities. If you do not wish to receive these offers, please tick the box below.

Please do not pass my information to any third party © IQPC Ltd 2007

Digital Conference on CD ROM

A digital version of the conference proceedings, including all the presentations in audio format

“An excellent service, an invaluable reference tool, easy to access and easy to store - all in all a top product”

Recent digital conferences available - £599 plus VAT each

- Drug Discovery Automation (November 2007)
- Lead-Finding Screening (May 2008)
- Polymorphism and Crystallisation (March 2008)
- Protein Stability (May 2008)
- Drug Discovery Automation (November 2007)

Please send me conference materials indicated above.

For further information please call: 0207 368 9300 or email: knowledgebank@iqpc.co.uk.
To search IQPC’s archived conference documentation, visit: www.iqpcknowledgebank.com.
Your order is risk free! If you are not happy with the content, simply return the products to us within seven days for a full refund.